890 related articles for article (PubMed ID: 19304423)
21. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?
Nathwani D
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii37-44. PubMed ID: 12730141
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections.
Logman JF; Stephens J; Heeg B; Haider S; Cappelleri J; Nathwani D; Tice A; van Hout BA
Curr Med Res Opin; 2010 Jul; 26(7):1565-78. PubMed ID: 20429820
[TBL] [Abstract][Full Text] [Related]
23. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
[TBL] [Abstract][Full Text] [Related]
25. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
[TBL] [Abstract][Full Text] [Related]
26. Comment: impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
Grau S; Mateu-de Antonio J; Marin-Casino M
Ann Pharmacother; 2006 Dec; 40(12):2280; author reply 2280-1. PubMed ID: 17105835
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
28. Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis).
Dodds TJ; Hawke CI
ANZ J Surg; 2009 Sep; 79(9):629-35. PubMed ID: 19895519
[TBL] [Abstract][Full Text] [Related]
29. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
30. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
[TBL] [Abstract][Full Text] [Related]
31. [New treatment option for gram-positive infections in critically ill patients - overview over linezolid].
Krueger WA; Unertl KE
Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Apr; 37(4):199-204. PubMed ID: 11967745
[TBL] [Abstract][Full Text] [Related]
32. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
33. Linezolid versus vancomycin for prosthetic joint infections: a cost analysis.
You JH; Lee GC; So RK; Cheung KW; Hui M
Infection; 2007 Jun; 35(4):265-70. PubMed ID: 17646907
[TBL] [Abstract][Full Text] [Related]
34. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
[TBL] [Abstract][Full Text] [Related]
36. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
Bassetti M; Baguneid M; Bouza E; Dryden M; Nathwani D; Wilcox M
Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():3-18. PubMed ID: 24580738
[TBL] [Abstract][Full Text] [Related]
37. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus.
Menzin J; Marton JP; Meyers JL; Carson RT; Rothermel CD; Friedman M
Am J Infect Control; 2010 Feb; 38(1):44-9. PubMed ID: 19762120
[TBL] [Abstract][Full Text] [Related]
38. Analysis of empiric antimicrobial strategies for cellulitis in the era of methicillin-resistant Staphylococcus aureus.
Phillips S; MacDougall C; Holdford DA
Ann Pharmacother; 2007 Jan; 41(1):13-20. PubMed ID: 17200425
[TBL] [Abstract][Full Text] [Related]
39. Linezolid eradicates MRSA better than vancomycin from surgical-site infections.
Weigelt J; Kaafarani HM; Itani KM; Swanson RN
Am J Surg; 2004 Dec; 188(6):760-6. PubMed ID: 15619496
[TBL] [Abstract][Full Text] [Related]
40. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
